Teva Pharmaceutical Industries Limited (NYSE:TEVA) issued an update on its FY17 earnings guidance on Thursday morning. The company provided earnings per share guidance of $4.30-4.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.73. The company issued revenue guidance of $22.8-23.2 billion, compared to the consensus revenue estimate of $23.43 billion.

Teva Pharmaceutical Industries Limited (NYSE TEVA) traded down 13.26% during midday trading on Friday, hitting $20.60. 93,317,085 shares of the company were exchanged. The stock has a market capitalization of $20.93 billion, a price-to-earnings ratio of 264.10 and a beta of 0.46. Teva Pharmaceutical Industries Limited has a 1-year low of $20.41 and a 1-year high of $55.79. The stock has a 50 day moving average of $32.05 and a 200-day moving average of $32.28. Teva Pharmaceutical Industries Limited also saw unusually large options trading activity on Thursday. Stock investors purchased 66,716 put options on the stock. This represents an increase of approximately 864% compared to the typical daily volume of 6,922 put options.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a return on equity of 16.38% and a net margin of 1.49%. The company had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.72 billion. During the same quarter in the prior year, the business posted $1.25 EPS. The company’s revenue for the quarter was up 12.9% compared to the same quarter last year. Equities analysts expect that Teva Pharmaceutical Industries Limited will post $4.65 earnings per share for the current year.

Several equities research analysts recently issued reports on TEVA shares. Vetr upgraded shares of Teva Pharmaceutical Industries Limited from a hold rating to a buy rating and set a $33.12 target price on the stock in a report on Tuesday, May 2nd. Deutsche Bank AG dropped their target price on shares of Teva Pharmaceutical Industries Limited from $45.00 to $43.00 and set a buy rating on the stock in a report on Friday, May 12th. CIBC restated a buy rating and issued a $43.00 target price on shares of Teva Pharmaceutical Industries Limited in a report on Friday, April 7th. Oppenheimer Holdings, Inc. set a $43.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the stock a buy rating in a report on Thursday, April 6th. Finally, Citigroup Inc. dropped their target price on shares of Teva Pharmaceutical Industries Limited from $47.00 to $42.00 and set a buy rating on the stock in a report on Tuesday, April 25th. One equities research analyst has rated the stock with a sell rating, twenty-two have issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of Hold and an average price target of $42.06.

ILLEGAL ACTIVITY WARNING: “Teva Pharmaceutical Industries Limited (TEVA) Updates FY17 Earnings Guidance” was published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/08/04/teva-pharmaceutical-industries-limited-teva-updates-fy17-earnings-guidance.html.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.